The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials.
Ishwaria Mohan Subbiah
No relevant relationships to disclose
Filip Janku
Research Funding - Novartis
Apostolia Maria Tsimberidou
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
Ahmed Omar Kaseb
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Vivek Subbiah
No relevant relationships to disclose
Kenneth R. Hess
No relevant relationships to disclose
Owais Akmal
No relevant relationships to disclose
Gerald Steven Falchook
No relevant relationships to disclose
Razelle Kurzrock
Honoraria - AstraZeneca; Roche/Genentech
Research Funding - AstraZeneca; Roche/Genentech